- Email: [email protected]
Production of Marek's disease vaccine by freeze drying fowl embryo cells with turkey herpes virus
Patent Report preventing diarrhoea. The microorganism used may be a 987P-producing E. coli bacterium; this may be a natural toxinproducer or an artificially produced bacterium from which the toxin-producing characteristic has been removed or weakened by e.g. genetic engineering. The bacterium may be a nontoxic E. coli strain which contains a plasmid which encodes the 987P fimbria production gene. 020-87
Preparation of foot-and-mouth disease virus in tissue culture: inactivated vaccine for pig
Seils H
Univ. lllinois Found. US 4596 707; 24 Jura 1986 A vaccine, conferri lg protection from Babesia infection, which contains a synthetic merozoite antigen. The antigen reacts specifically in vitro with serum antibodies which neutralize the infectivity of Babesia merozoites. 1129-87
Novel immunostimulating glycoproteins
E. Germany 235 481; 17 November 1986
Roussel Uclaf
The recovery of foot-and-mouth disease virus (FMDV) from tissue culture for the preparation of inactivated biologically active vaccines for pigs comprises cultivating the tissue culture from permanent cells in large round flasks (preferably 10 1) using a known process, especially a roll process, of cultivation. After a closed cell lawn has been formed, this is infected with FMDV at the multiplication phase of the virus and the culture suspended in a medium. The virus is multiplied for 12 36 h and then harvested by conventional methods. Preferably the cells are cultivated in the flasks in a medium based on physiological saline with additives. This process can be used for the production of vaccines suitable for the immunization of pigs. Relatively large fermentation flasks can be used and the cell culture medium is of simple composition. In an example BHK-21 cells were cultivated in Roux flasks for continuous cultivation using Eagle's medium. Inactivation of the virus is carried out using heat and formalin. 021-87
Quality assurance and testing in vaccine production for determination of surface antigens of e.g. Escherichia coil
US 4596 709; 24 June 1986 Immunostimulating glycoproteins obtained from Klebsiella pneumoniae. The glycoproteins are water soluble and have a molecular weight of about 350 000 daltons. They are recovered by gel filtration of a glycoprotein fraction prepared from a lysate of a Klebsiella pneumoniae culture. 030-87
Safe vaccine for hepatitis containing polymerized serum albumin
Univ. Cali]: US 4596 792; 24 June 1986 A vaccine effective against hepatitis infection in which the immunogenic component is polymerized serum albumin, free from hepatitis virus-derived protein or nucleic acid. The serum albumin is administered as a six to twelve unit polymer with an acceptable adjuvant. 031 87
Synthetic polypeptide fragments
Univ. Tennessee Res. Corp.
Kludas U E. Germany 235 499:17 November 1986
Babesia parasite antigen useful in vaccine and diagnostic reagent
022-87
Production of Marek's disease vaccine by freeze drying fowl embryo cells with turkey herpes virus
US 4597 967; 1 July 1986 A family of synthetic peptide antigens capable of eliciting an immune response to Streptococcus pyogenes without inducing antibodies cross-reactive with heart-muscle antigens. 032-87
Friedrich-Loeffler Inst. E. Germany 235 775; 1 December 1986
023-87
Production of live vaccines e.g. Salmonella from pathogen mutants with resistance to ! or 2 antibacterial agents
Karl-Marx- Univ. E. Germany 235 828; 1 December 1986
024-87
Purified non-A, non-B hepatitis virus antigen useful in vaccine
U.S. Dept. Commerce Eur. 194 2117; l December 1986
Scripps US 4599 231; 8 July 1986 An anti-hepatitis B virus vaccine containing at least two synthetic peptides, one carrying a B cell determinant and the other a T cell determinant. The vaccine stimulates both the production of antibodies and the proliferation of T-cells. 033-87
025-87
Injectable Bordetella bronchiseptica vaccine for preventing atrophic rhinitis and turbinate atrophy in pigs
Vaccine against Neisseria meningitidis group B serotype 2 invasive disease
US Dept. Health Human Serv.
Io wa-State- Univ. Netherlands 179 875; 1 December 1986
Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
026-87
US 4601 903:22 July 1986
A Neisseria meningitidis vaccine containing one group B, New Bordetella pertussis toxin clone construction and characterization: gene cloning and expression in Escherichia coli; production of pure antigen peptides for use in vaccines against whooping cough
serotype 2b, lipopolysaccharide depleted outer membrane antigen. The vaccine is effective against N. meningitidis group B serotypes 2a and 2b. 1/34-87
US Dept. Health Human Serv.
Synthetic heat-stable enterotoxin polypeptide of E. coil and multimers thereof
US 6843 727; 1 December 1986
027-87
Production of conformation-independent antigens by denaturing the conformation-dependent antigenic determinant for analysis and vaccine against hepatitis B virus
Scripps World 86/15 189; 1 December 1986 74
Vaccine, Vol. 5, March 1987
1128-87
Scripps US 4603 049; 29 July 1986 A polymerized synthetic peptide, in which the monomer has the sequence of antigenic portions of the heat-stable E. coli enterotoxin. 035-87
Preparation of foot-and-mouth disease virus in tissue culture: inactivated vaccine for pig
Seils H
Univ. lllinois Found. US 4596 707; 24 Jura 1986 A vaccine, conferri lg protection from Babesia infection, which contains a synthetic merozoite antigen. The antigen reacts specifically in vitro with serum antibodies which neutralize the infectivity of Babesia merozoites. 1129-87
Novel immunostimulating glycoproteins
E. Germany 235 481; 17 November 1986
Roussel Uclaf
The recovery of foot-and-mouth disease virus (FMDV) from tissue culture for the preparation of inactivated biologically active vaccines for pigs comprises cultivating the tissue culture from permanent cells in large round flasks (preferably 10 1) using a known process, especially a roll process, of cultivation. After a closed cell lawn has been formed, this is infected with FMDV at the multiplication phase of the virus and the culture suspended in a medium. The virus is multiplied for 12 36 h and then harvested by conventional methods. Preferably the cells are cultivated in the flasks in a medium based on physiological saline with additives. This process can be used for the production of vaccines suitable for the immunization of pigs. Relatively large fermentation flasks can be used and the cell culture medium is of simple composition. In an example BHK-21 cells were cultivated in Roux flasks for continuous cultivation using Eagle's medium. Inactivation of the virus is carried out using heat and formalin. 021-87
Quality assurance and testing in vaccine production for determination of surface antigens of e.g. Escherichia coil
US 4596 709; 24 June 1986 Immunostimulating glycoproteins obtained from Klebsiella pneumoniae. The glycoproteins are water soluble and have a molecular weight of about 350 000 daltons. They are recovered by gel filtration of a glycoprotein fraction prepared from a lysate of a Klebsiella pneumoniae culture. 030-87
Safe vaccine for hepatitis containing polymerized serum albumin
Univ. Cali]: US 4596 792; 24 June 1986 A vaccine effective against hepatitis infection in which the immunogenic component is polymerized serum albumin, free from hepatitis virus-derived protein or nucleic acid. The serum albumin is administered as a six to twelve unit polymer with an acceptable adjuvant. 031 87
Synthetic polypeptide fragments
Univ. Tennessee Res. Corp.
Kludas U E. Germany 235 499:17 November 1986
Babesia parasite antigen useful in vaccine and diagnostic reagent
022-87
Production of Marek's disease vaccine by freeze drying fowl embryo cells with turkey herpes virus
US 4597 967; 1 July 1986 A family of synthetic peptide antigens capable of eliciting an immune response to Streptococcus pyogenes without inducing antibodies cross-reactive with heart-muscle antigens. 032-87
Friedrich-Loeffler Inst. E. Germany 235 775; 1 December 1986
023-87
Production of live vaccines e.g. Salmonella from pathogen mutants with resistance to ! or 2 antibacterial agents
Karl-Marx- Univ. E. Germany 235 828; 1 December 1986
024-87
Purified non-A, non-B hepatitis virus antigen useful in vaccine
U.S. Dept. Commerce Eur. 194 2117; l December 1986
Scripps US 4599 231; 8 July 1986 An anti-hepatitis B virus vaccine containing at least two synthetic peptides, one carrying a B cell determinant and the other a T cell determinant. The vaccine stimulates both the production of antibodies and the proliferation of T-cells. 033-87
025-87
Injectable Bordetella bronchiseptica vaccine for preventing atrophic rhinitis and turbinate atrophy in pigs
Vaccine against Neisseria meningitidis group B serotype 2 invasive disease
US Dept. Health Human Serv.
Io wa-State- Univ. Netherlands 179 875; 1 December 1986
Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
026-87
US 4601 903:22 July 1986
A Neisseria meningitidis vaccine containing one group B, New Bordetella pertussis toxin clone construction and characterization: gene cloning and expression in Escherichia coli; production of pure antigen peptides for use in vaccines against whooping cough
serotype 2b, lipopolysaccharide depleted outer membrane antigen. The vaccine is effective against N. meningitidis group B serotypes 2a and 2b. 1/34-87
US Dept. Health Human Serv.
Synthetic heat-stable enterotoxin polypeptide of E. coil and multimers thereof
US 6843 727; 1 December 1986
027-87
Production of conformation-independent antigens by denaturing the conformation-dependent antigenic determinant for analysis and vaccine against hepatitis B virus
Scripps World 86/15 189; 1 December 1986 74
Vaccine, Vol. 5, March 1987
1128-87
Scripps US 4603 049; 29 July 1986 A polymerized synthetic peptide, in which the monomer has the sequence of antigenic portions of the heat-stable E. coli enterotoxin. 035-87